Stock Analiz

ADC Therapeutics SA ADCT

Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026

$1.34Market cap $171M
Open the interactive analysis →

ADC Therapeutics SA (ADCT) is a healthcare company listed in the US with a market value of about $171M. In the twelve months to September 30, 2026 it had revenue of $85M and net income of -$81M, a net margin of -95.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -73%.

About ADC Therapeutics SA

ADC Therapeutics SA is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $1M in 2018 to $81M in 2025, growth of about 84.0% a year. It was profitable in 0 of the last 8 years in our data. It spends 128% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.0
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-58.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)14.8%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-299.3%
ROIC (5-yr avg.)-73.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$85M$81M$71M$70M$210M$34M$0$2M$1M
Net income-$81M-$143M-$158M-$240M-$157M-$230M-$246M-$116M-$123M
Free cash flow-$101M-$141M-$125M-$122M-$139M-$237M-$170M-$122M-$122M
EPS (diluted)$-0.46$-1.12$-1.24$-1.88$-1.23$-1.80$-1.93$-0.91$-0.96
Net margin-95.7%-175.3%-222.8%-345.1%-74.9%-678.2%—-4977.9%-10797.9%
ROIC————-49.5%-96.6%-46.3%-84.9%-78.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does ADC Therapeutics SA pay a dividend?

Not currently.

Is ADC Therapeutics SA a good stock to buy?

We do not give buy or sell advice. ADC Therapeutics SA scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.